<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
The FDA has approved Provention Bio Inc’s (NASDAQ: PRVB) proceeding to populate the popPK model with data collected from patients receiving therapeutic doses of teplizumab PK/PD substudy. Related Link: Provention Bio’s Teplizumab Application Receives CRL For Type-1 Diabetes; Stock Drops
...read full article on Benzinga
